p53 pten control neural glioma stem/progenitor cell renewal differentiation
glioblastoma gbm highly lethal brain tumour presenting one two subtypes distinct clinical histories molecular profiles primary gbm subtype presents acutely high-grade disease typically harbours mutations egfr pten ink4a/arf also known cdkn2a secondary gbm subtype evolves slow progression low grade disease classically possesses pdgf tp53 events- show concomitant central nervous system cns specific deletion p53 pten mouse cns generates penetrant acute onset high grade malignant glioma phenotype notable clinical pathological molecular resemblance primary gbm humans genetic observation prompted tp53 pten mutational analysis human primary gbm demonstrating unexpectedly frequent inactivating mutations tp53 well expected pten mutations integrated transcriptomic profiling silico promoter analysis functional studies murine neural stem cells nscs established dual singular inactivation p53 pten promotes undifferentiated state high renewal potential drives increased myc protein levels associated signature functional studies validated increased myc activity potent contributor impaired differentiation enhanced renewal nscs doubly null p53 pten p53-/- pten-/- well tumour neurospheres tnss derived model myc also serves maintain robust tumorigenic potential p53-/- pten-/- tnss murine modelling studies together confirmatory transcriptomic/ promoter studies human primary gbm validate pathogenetic role common tumour suppressor mutation profile human primary gbm establish myc important target cooperative actions p53 pten regulation normal malignant stem/ progenitor cell differentiation self renewal tumorigenic potential
